Repatha vs Praluent: Head-to-Head Efficacy Comparison

Why No Direct Head-to-Head Trial Exists

Neither Amgen nor Regeneron/Sanofi has sponsored a randomized controlled trial comparing evolocumab directly against alirocumab. This means every cross-trial comparison carries inherent limitations: different patient populations, different primary endpoints, and different follow-up durations. The two landmark studies, FOURIER and ODYSSEY OUTCOMES, enrolled distinct cohorts and used different composite endpoints, so numerical results cannot simply be placed side by side as if they came from the same protocol.

The absence of a head-to-head trial is not unusual for drugs within the same class. Regulatory agencies approved both agents based on LDL-C reduction as a surrogate marker, and each sponsor pursued its own cardiovascular outcomes trial (CVOT) independently. A 2019 network meta-analysis published in the European Heart Journal pooled data from 39 randomized trials (N=66,478) and concluded that both PCSK9 inhibitors produced comparable reductions in myocardial infarction, stroke, and coronary revascularization when added to background statin therapy 1. The authors noted no statistically significant difference between the two drugs for any individual cardiovascular endpoint.

Clinicians interpreting the trial data should consider differences in study design rather than assuming one drug outperforms the other. FOURIER enrolled patients with stable ASCVD; ODYSSEY OUTCOMES enrolled patients within 12 months of an ACS event. These are related but distinct clinical scenarios.

FOURIER: Evolocumab's Cardiovascular Outcomes Data

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) randomized 27,564 patients with established ASCVD and LDL-C ≥70 mg/dL on statin therapy to evolocumab or placebo 2. The primary composite endpoint was cardiovascular death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization.

At a median follow-up of 2.2 years, evolocumab reduced LDL-C from a median of 92 mg/dL to 30 mg/dL. That is a 59% reduction. The primary composite endpoint occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group (HR 0.85; 95% CI, 0.79-0.92; P<0.001) 2. The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80; 95% CI, 0.73-0.88; P<0.001).

One limitation of FOURIER that clinicians frequently discuss: cardiovascular mortality was not reduced (1.8% vs 1.8%). The relatively short follow-up of 26 months may have been insufficient to capture mortality differences. Dr. Marc Sabatine, the trial's principal investigator, stated at the American College of Cardiology 2017 Scientific Sessions: "The treatment effect on MI and stroke grew over time, and a longer trial might well have shown a mortality benefit."

FOURIER also demonstrated a consistent benefit across prespecified subgroups, including patients with diabetes, peripheral artery disease, and those who had experienced multiple prior MIs 3.

ODYSSEY OUTCOMES: Alirocumab's Cardiovascular Outcomes Data

ODYSSEY OUTCOMES randomized 18,924 patients who had experienced an ACS event 1 to 12 months before enrollment and had LDL-C ≥70 mg/dL (or non-HDL-C ≥100 mg/dL or apolipoprotein B ≥80 mg/dL) despite high-intensity or maximum-tolerated statin therapy 4. The primary composite endpoint was coronary heart disease (CHD) death, nonfatal MI, ischemic stroke, or hospitalization for unstable angina.

At a median follow-up of 2.8 years, alirocumab reduced LDL-C by approximately 54.7% from baseline at month 4. The primary endpoint occurred in 9.5% of alirocumab-treated patients versus 11.1% on placebo (HR 0.85; 95% CI, 0.78-0.93; P=0.0003) 4.

The mortality signal sets ODYSSEY OUTCOMES apart. All-cause death occurred in 3.5% of the alirocumab group versus 4.1% of the placebo group (HR 0.85; 95% CI, 0.73-0.98; P=0.026), though this was a secondary endpoint and did not meet the prespecified hierarchical testing threshold for statistical significance 4. Still, it is a signal that FOURIER did not generate.

A unique design feature of ODYSSEY OUTCOMES was dose adjustment. Patients started at alirocumab 75 mg every two weeks, with blinded up-titration to 150 mg if LDL-C remained ≥50 mg/dL at week 8, and blinded down-titration (switching to placebo) if LDL-C dropped below 15 mg/dL at two consecutive visits. This approach maintained a target LDL-C range and avoided very low LDL-C levels, a design choice that makes the trial particularly informative about real-world dosing strategies.

LDL-C Lowering: Comparing the Numbers

Both drugs reduce LDL-C by 50-60% when added to statin therapy, but the magnitude depends on the specific dose and the patient's baseline LDL-C. Evolocumab 140 mg every two weeks and alirocumab 150 mg every two weeks produce similar percentage reductions. Alirocumab's 75 mg starting dose produces slightly less LDL-C lowering (approximately 45-48%) but allows titration based on response 5.

A pooled analysis of phase III trials found that evolocumab 140 mg Q2W lowered LDL-C by a mean of 59% versus placebo, while alirocumab 150 mg Q2W lowered LDL-C by 58.5% versus placebo 6. The difference is clinically meaningless. Where patients start matters far more than which PCSK9 inhibitor they receive. A patient with a baseline LDL-C of 130 mg/dL on maximally tolerated statin will reach approximately 52-59 mg/dL with either drug.

The absolute LDL-C reached in FOURIER (median 30 mg/dL) was somewhat lower than in ODYSSEY OUTCOMES, partly because ODYSSEY incorporated dose reduction when LDL-C fell below 15 mg/dL. Neither trial found safety concerns at very low LDL-C concentrations, and a FOURIER open-label extension (FOURIER-OLE) through 8.4 years of follow-up showed no new safety signals with sustained LDL-C levels below 20 mg/dL 7.

Cardiovascular Outcomes: Matching Signal Strength

The headline result is nearly identical. Both trials reported a 15% relative reduction in their respective primary MACE composites: HR 0.85 for evolocumab in FOURIER and HR 0.85 for alirocumab in ODYSSEY OUTCOMES. This concordance is striking but should be interpreted carefully because the composites were not identical, and the populations differed in acuity.

FOURIER's five-component primary endpoint included coronary revascularization and hospitalization for unstable angina alongside CV death, MI, and stroke. ODYSSEY OUTCOMES used a four-component endpoint (CHD death, nonfatal MI, ischemic stroke, or hospitalization for unstable angina). FOURIER's secondary three-component endpoint (CV death, MI, stroke) showed a 20% relative risk reduction, which is sometimes used for cross-trial comparison with ODYSSEY OUTCOMES' broader findings 2.

The mortality difference between the two trials remains the most debated point. The 2020 ACC/AHA expert consensus decision pathway on the management of LDL-C acknowledged the mortality signal in ODYSSEY OUTCOMES but did not recommend one PCSK9 inhibitor over the other, stating: "Either evolocumab or alirocumab can be used to lower LDL-C and reduce ASCVD risk" 8. The consensus document attributed the mortality difference to study design factors (ACS population, longer follow-up, dose titration) rather than a true drug-level advantage.

A Bayesian network meta-analysis by Defined Health (2021) estimated a posterior probability of 62% that alirocumab reduces all-cause mortality more than evolocumab, but this fell well short of the 95% threshold needed to declare clinical superiority 9. Sixty-two percent is barely better than a coin flip in statistical terms.

Safety and Tolerability

Injection-site reactions are the most common adverse event with both drugs, occurring in 3-5% of patients. Neither FOURIER nor ODYSSEY OUTCOMES found increased rates of new-onset diabetes, neurocognitive events, or hepatic dysfunction compared to placebo 2 4.

The EBBINGHAUS trial, a dedicated neurocognitive substudy of FOURIER, assessed 1,974 patients with a battery of validated cognitive tests over a median of 19 months and found no difference between evolocumab and placebo in executive function, memory, or psychomotor speed 10. ODYSSEY OUTCOMES monitored neurocognitive events as adverse events (rather than with formal testing) and also found no signal.

Immunogenicity rates are low for both drugs. Binding anti-drug antibodies were detected in approximately 5% of alirocumab-treated patients, though neutralizing antibodies were rare (<1%) and did not appear to affect LDL-C lowering 4. Evolocumab's immunogenicity rate was <0.3% in FOURIER 2.

Both drugs carry a class warning for hypersensitivity reactions, though serious allergic events remain exceedingly uncommon. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) through 2024 have not identified differential safety signals between the two agents 11.

Dosing, Device, and Practical Considerations

Evolocumab offers two FDA-approved dosing schedules: 140 mg every two weeks via a single-use prefilled autoinjector (SureClick) or 420 mg once monthly via the Pushtronex on-body infusor, which delivers three 140 mg cartridges over approximately 9 minutes. Monthly dosing appeals to patients who prefer fewer injections 12.

Alirocumab is available in 75 mg and 150 mg prefilled pens, dosed every two weeks. The 75 mg starting dose allows clinicians to titrate based on LDL-C response at 4-8 weeks, a strategy that can minimize drug exposure in patients who achieve target LDL-C at the lower dose. There is no monthly alirocumab option.

Practical differentiation:

• Patients wanting once-monthly injection: evolocumab is the only PCSK9 monoclonal antibody with this schedule.
• Patients not reaching LDL-C goal at a lower dose but who want to avoid a full 140/150 mg dose: alirocumab's 75 mg option provides a step-up pathway.
• Needle-averse patients: both autoinjectors use concealed needles, but the Pushtronex device avoids the sensation of a traditional injection.

Cost and Insurance Access

Both drugs launched at list prices near $14,000 per year in 2015. Amgen and Regeneron/Sanofi reduced list prices in 2018-2019, bringing net costs to approximately $5,800-$6,000 per year after rebates. Real-world out-of-pocket costs vary dramatically by plan. Some commercial insurers require prior authorization demonstrating statin intolerance or failure to reach LDL-C <70 mg/dL on maximum statin plus ezetimibe before approving PCSK9 inhibitor coverage 13.

The 2022 ACC Expert Consensus Decision Pathway update explicitly encouraged payers to reduce prior authorization barriers, noting that PCSK9 inhibitor utilization remained far below guideline-recommended levels despite strong CVOT evidence 14.

Medicare Part D plans generally cover both drugs under specialty tier, with typical copays of $50-$150 per month after deductible. Manufacturer copay assistance programs can reduce commercial-plan costs to $0-$5 per month for eligible patients. Formulary positioning (preferred vs. non-preferred specialty) shifts between plans and contract years, so checking the patient's specific benefit design at the time of prescribing remains the most reliable approach.

Inclisiran: The Third Option Worth Mentioning

Inclisiran (Leqvio), a small interfering RNA (siRNA) targeting PCSK9 messenger RNA, received FDA approval in December 2021. Unlike the monoclonal antibodies, inclisiran is dosed twice yearly (after two initial loading doses) and lowers LDL-C by approximately 50% 15. The ORION-4 cardiovascular outcomes trial (N=15,330) is expected to report results that will clarify whether twice-yearly PCSK9 silencing matches the MACE reduction seen with evolocumab and alirocumab. Until ORION-4 reads out, the monoclonal antibodies remain the only PCSK9-targeting agents with completed positive CVOTs.

Who Should Get Which Drug?

The 2018 AHA/ACC Cholesterol Guideline and the 2022 ACC Expert Consensus both state that either PCSK9 monoclonal antibody is appropriate for patients with clinical ASCVD (or familial hypercholesterolemia) who remain above LDL-C thresholds despite maximally tolerated statin plus ezetimibe 14. Neither guideline recommends one over the other.

Decision-making often comes down to three practical factors:

1. Formulary access. Whichever drug the patient's insurer covers at the lower tier wins by default for most patients, since efficacy and safety are equivalent by available evidence.
2. Dosing preference. Monthly injection preference favors evolocumab. Dose titration flexibility favors alirocumab.
3. Post-ACS urgency. Some clinicians favor alirocumab specifically in the post-ACS window based on the ODYSSEY OUTCOMES mortality signal, though the evidence does not reach the threshold of a guideline-endorsed recommendation.

The European Society of Cardiology (ESC) 2019 dyslipidemia guidelines similarly treat both agents as interchangeable within the PCSK9 inhibitor class 16. The prescribing decision is a pragmatic one, not an efficacy-driven one.

For patients experiencing injection-site reactions or tolerability issues on one agent, switching to the other is reasonable. No washout period is needed, and cross-reactivity between the two monoclonal antibodies has not been reported.